1. Scrip
  2. >>Business
  3. >>Deals

Novo Nordisk Bets $256m On Mystery Molecule

 
• By Elizabeth Cairns

The Danish group has licensed an unnamed product with an unknown mechanism.  

3d different tablets and pills on a white background with question marks

For any other company, spending €235m ($256m) on a preclinical program with an unproven mechanism might be a punchy move. But Novo Nordisk A/S has money to burn thanks to its wildly successful diabetes and obesity therapies, so taking a leap into the unknown is not as huge a risk as it might be.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.